The share price of a small investment group soared on news that one its portfolio companies is involved in developing a Covid-19 test, despite no indication of the financial impact and whether the test might actually be commercialised. Another software group supporting the UK healthcare sector commits to its full year dividend, a rare thing.
EMIS: continuing to invest and a dividend is paid
UK leader in connected healthcare software EMIS Group (LON:EMIS) has confirmed that trading for the year to date is in line with expectations.
A recent initiative in which they are involved includes a research collaboration for a trial testing the effectiveness of various treatments in the early phases of Covid-19.
The balance sheet remains in good shape with cash of £40.0m at 30 April 2020, no bank…
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.